A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Urothelial Cancer
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
Most Recent Events
- 09 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2026.
- 16 Sep 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2026.